Allan Riting Liu 刘日廷

Allan Riting Liu 刘日廷

Dr. Allan Riting Liu is currently the vice president/senior advisor at Wanbang Biopharmaceutical Group (a subsidiary of Fosun Pharma)for new drug/business development. After graduating from Sun Yat-sen Medical University in 1989, he worked as a sales manager at Xian-Janssen (a J&J). In 1993, he worked as a visiting scholar at New York Medical College. Then he did Ph.D. studies in biochemistry at University of Texas (UT)/M.D. Anderson Cancer Center. After his post-doctoral research at University of Delaware, he worked as a scientist at Eli Lilly’s headquarter for developing osteoporosis and cancer drugs. He also attained an MBA at Purdue University receiving the best scholarship offer. In 2006 after he came back to China, he worked as the director of business development at Fosun Pharma.

Dr. Liu is an internationally well-known professional and among the most outstanding experts in China on pharmaceutical licensing and new drug development. He led to complete about 10 international deals of licensing/technology transfers including the licensing deals for glargine and rh insulin from India, a co-development deal for a FDA phase III potential blockbuster for stroke from Israel. He also developed many new drug proposals for in-house R&D and led the preclinical research, clinical trials and new drug registration for the in-licensed development products. At a doctoral research at UT’s department of integrative biology (chaired by the Nobel Prize winner Dr. Ferid Murad), he became the first scientist in the world to discover that psychosine can mobilize intracellular calcium. In 2003, he received an honor/award as Guidant Scholar offered by Guidant Foundation (U.S.). In 2008, he received an honor as One-Million-Yuan-Subsidized Top Talent offered by Jiangsu Provincial Government of China.

Upcoming Events
Biologics World Nordic 2019 5 – 7 March 2019, Stockholm, Sweden

Biologics World Nordic will be the only focused biologic drugs and vaccines conference in the Nordic region. We will bring together the complete network of the Nordic biologics industry including region’s smaller Biopharma, Big Pharma, International Biopharma, CMOs, CROs, Technocrats & Solution Providers.

.. Read More

Biologics World Taiwan 2019 26 – 28 March 2019, Singapore

In March 2019, 7th Annual Biologics World Taiwan – the ONLY biologics and biosimilars focused platform in Taiwan – will again come to Taipei and bring together Taiwanese and international biopharma leaders, innovative biotechs, and technocrats!

.. Read More

Biologics Manufacturing Korea 2019 28 – 30 May 2019, Singapore

Since 2012, Biologics Manufacturing Korea has witnessed huge success in bringing over 550 biologics industry pioneers from both Korea and overseas. With the mission to facilitate development and manufacturing of high-quality biologic drugs and vaccines in Korea for the world market, Biologics Manufacturing Korea is going to continue its legacy.

.. Read More